Symbicort® COPD (budesonide/formoterol)

Symbicort® (budesonide/formoterol) Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist 

Chronic obstructive pulmonary disease (COPD) and Symbicort®

Tolerability

Symbicort® tolerability profile1-3

Since Symbicort® contains both budesonide and formoterol, the same pattern of undesirable effects reported for these substances may occur.1-3

The most common drug-related adverse events are pharmacologically predictable side effects of β2-adrenoceptor agonist therapy, such as tremor and palpitations; these tend to be mild and usually disappear within a few days of treatment.1-3


An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids.1-3

*Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to <1/100). Only very common, common and uncommon side effects are presented. Please refer to the relevant SmPC for the full list of adverse events.1-3

**Only applies to Symbicort® 200/6 and 400/12.1,2